NASDAQ$DSGN
Design Therapeutics Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Design Therapeutics reported third quarter 2024 financial results and reviewed near-term milestones for GeneTAC™ portfolio.
Design Therapeutics reported a net loss of $13.0 million for the third quarter of 2024. The company's cash, cash equivalents, and marketable securities totaled $254.1 million as of September 30, 2024, expected to fund operations into 2029. Phase 1 trial in FECD initiated with data expected in the first half of 2025.
- Phase 1 trial initiated for Fuchs Endothelial Corneal Dystrophy (FECD) with data expected in the first half of 2025.
- Friedreich Ataxia (FA) program on track to initiate Phase 1 study in the first half of 2025.
- Research pipeline advancing with programs in Myotonic Dystrophy Type-1 (DM1) and Huntington’s Disease (HD).
- Cash and securities of $254.1 million expected to fund operations through up to four potential clinical proof-of-concept data sets.
Headline financials
Revenue & EPS history
Design Therapeutics · Revenue · Quarterly
$0
Forward guidance
Design Therapeutics anticipates a busy first half of 2025 with data expected from the ongoing Phase 1 trial in FECD and the start of clinical activities for the FA program.
Tailwinds
- Data expected from ongoing Phase 1 trial in FECD in the first half of 2025.
- FA program on track to initiate Phase 1 study in the first half of 2025.
- Beginning FA patient dosing later in 2025.
- Advancing preclinical characterization of lead molecules for Huntington’s disease (HD).
- Advancing preclinical characterization of lead molecules for myotonic dystrophy type-1 (DM1).
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2024
-2.2%
Avg return
Earnings day
+1.7%
Avg return
5 days after
+3.2%
Avg return
30 days after
50%
10 / 20 earnings
Positive
+15.1%
Q4 2023
Best reaction
-71.7%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.0% | +3.8% | -16.2% | |
| Q4 2025 | +3.2% | +0.7% | +26.1% | |
| Q3 2025 | +10.7% | +10.8% | +42.2% | |
| Q2 2025 | -8.9% | +14.5% | +48.3% | |
| Q1 2025 | +0.3% | +10.3% | +10.3% | |
| Q4 2024 | +0.4% | +2.5% | -27.2% | |
| Q3 2024 | -1.9% | +16.3% | +7.9% | |
| Q1 2024 | +1.7% | -3.0% | -17.9% | |
| Q4 2023 | +15.1% | +50.8% | +48.4% | |
| Q3 2023 | +13.9% | +10.4% | +27.4% | |
| Q2 2023 | -71.7% | -72.8% | -65.2% | |
| Q1 2023 | -12.2% | -12.6% | -26.4% | |
| Q4 2022 | -0.6% | -8.1% | -24.8% | |
| Q3 2022 | -0.3% | -0.8% | -9.7% | |
| Q2 2022 | +0.3% | +13.5% | +5.5% | |
| Q1 2022 | -1.5% | -2.4% | +30.9% | |
| Q4 2021 | -1.8% | -0.8% | -10.0% | |
| Q3 2021 | +4.8% | +10.7% | -3.8% | |
| Q2 2021 | +9.9% | +7.9% | +19.7% | |
| Q1 2021 | -6.0% | -18.0% | -1.8% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro